January 6, 2021
Evan Diamond comments on President Trump signing into law a bill that updates U.S. Food and Drug Administration regulations on patents for drugs
October 7, 2020
Evan Diamond discusses the Federal Circuit’s decision to revive a $235M induced infringement verdict against Teva
June 17, 2020
King & Spalding IP Practices and Individuals Recognized in the IAM Patent 1000 Guide
June 2, 2020
Gerald Flattmann, Lori Gordon, Vanessa Yen and Evan Diamond advise Alexion on its patent settlement with Amgen
November 10, 2020
13th Annual King & Spalding Medical Device Summit
October 28, 2020
Testing the Limits: New Developments in Antitrust Targeting Biologics/Biosimilars Competition
November 12, 2019
12th Annual King & Spalding Pharmaceutical University
June 24, 2019
Evan Diamond, Vanessa Yen to Speak at ACI’s 2019 Summit on Biosimilars
April 7, 2021
“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What is Required, and What to Expect?
February 12, 2021
GSK v. Teva and Induced Infringement by AB-Rated Generics: Where are we now?
February 3, 2021
Challenging Therapeutics IP After Fed. Circ. Drink Can Ruling